Actavis, Inc. to Present at the Barclays 2013 Global Healthcare Conference

Wed Feb 27, 2013 9:16am EST

* Reuters is not responsible for the content in this press release.

For best results when printing this announcement, please click on the link
below:

http://pdf.reuters.com/pdfnews/pdfnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20130227:nPnNY67529


PARSIPPANY, N.J.,  Feb. 27, 2013  /PRNewswire/ -- Actavis, Inc. (NYSE: ACT), a
leading specialty pharmaceutical company, announced today that  Paul Bisaro,
Actavis' President and Chief Executive Officer, will provide an overview and
update of the Company's business at the Barclays 2013 Global Healthcare
Conference on  Tuesday, March 12, 2013  at  10:15AM ET  at The Loews Miami Hotel
in  Miami, Florida. The presentation will be webcast live and can be accessed on
Actavis' Investor Relations Web site at  http://ir.actavis.com.  The webcast can
also be accessed at the following URL:  

http://cc.talkpoint.com/barc002/031213a_lp/?entity=50_D17TFJP

An archived version will be available approximately one hour after the live
presentation ends and can be accessed at the same locations for 90 days.

About Actavis, Inc.

Actavis, Inc. (NYSE: ACT) is a global, integrated specialty pharmaceutical
company focused on developing, manufacturing and distributing generic, brand and
biosimilar products.  The Company has global and U.S. headquarters in 
Parsippany, New Jersey, USA, and international headquarters in Zug, Switzerland.
  

Actavis is the world's third-largest generics prescription drug manufacturer. 
Operating as Actavis Pharma, the Company develops, manufactures and markets
generic, branded generic, legacy brands and Over-the-Counter (OTC) products in
more than 60 countries.  The Company is ranked in the top 3 in 12 global
markets, the top 5 in 16 global markets, and in the top 10 in 33 global markets.
  Actavis Pharma also develops and out-licenses generic pharmaceutical products
outside the U.S. through its Medis third-party business, the world's largest
generic pharmaceutical out-licensing business. Medis has more than 300 customers
globally, and offers a broad portfolio of more than 200 products.   

Actavis Specialty Brands is the Company's global branded specialty
pharmaceutical business, which develops and markets a portfolio of approximately
40 products principally in  the United States  and  Canada  that are focused in
the Urology and Women's Health therapeutic categories.  Actavis Specialty Brands
is committed to developing and marketing biosimilars products in Women's Health,
Oncology and other therapeutic categories, and currently has a portfolio of 5
biosimilar products in development.  

Actavis Global Operations has more than 30 manufacturing and distribution
facilities around the world, with a capacity of approximately 44 billion units
annually.  Actavis Global Operations also includes Anda, Inc., the
fourth-largest U.S. generic pharmaceutical product distributor in  the United
States.

For press release and other company information, visit Actavis' Web site at 
http://www.actavis.com.

 CONTACTS:  Investors:        
            Lisa DeFrancesco  
            (862) 261-7152    
                              
            Media:            
            Charlie Mayr      
            (862) 261-8030    


(Logo:  http://photos.prnewswire.com/prnh/20130124/NY47381LOGO )



SOURCE  Actavis, Inc.

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.